Tech Company Financing Transactions
Immutrin Funding Round
Immutrin closed a $87 million Series A funding round on 3/24/2026. Backers included Frazier Life Sciences, Cambridge Enterprise and Cambridge Innovation Capital.
Transaction Overview
Company Name
Announced On
3/24/2026
Transaction Type
Venture Equity
Amount
$87,000,000
Round
Series A
Investors
Proceeds Purpose
The proceeds from this financing will fund Immutrin's lead asset through clinical proof of concept in ATTR cardiomyopathy, a serious and often fatal form of amyloidosis.
Company Information
Company Status
Private & Independent
Industry
Life Sciences
Mailing Address
22 Station Road
Cambridge, CB1 2JD
UK
Cambridge, CB1 2JD
UK
Phone
Undisclosed
Website
Email Address
Overview
Immutrin is a biotechnology company developing next generation antibody therapy to deplete systemic amyloid deposits and reverse amyloidosis. The Company's lead asset is being developed for the treatment of ATTR cardiomyopathy, a serious and progressive form of amyloidosis. Immutrin's antibody is a potential best-in-class therapy, with a unique mechanism of action designed to selectively and exclusively remove established amyloid fibrils.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Sef Kurstjens
Chief Executive Officer
Mihriban Tuna
Chief Financial Officer
Tolga Hassan
Co-Founder
Daniel Christ
Co-Founder
Mark Pepys
Co-Founder
Gregory Winter
VP - R & D
Kin Leung
Browse more venture capital transactions:
Prev: 3/24/2026: Myosin Therapeutics venture capital transaction
Next: 3/24/2026: Stateful Robotics venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to document every notable VC transaction. VC investment data records on this site come from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs